Investors turn to biotech as vaccine roll-out cools sentiment on big pharma
Other sectors set to benefit as lockdown eases
Sectors such as telemedicine could boom over the course of the year
Any halo earned from helping tackle the Covid-19 pandemic is likely to be short-lived for big pharma, according to asset managers who are turning their sights towards biotech and telehealth as the world slowly returns to normal.
On 8 December 2020, England became the first country to roll out a Covid-19 vaccine, a jab developed by Pfizer and BioNTech.
In the months leading up to that, the healthcare sector took a leading role during the Covid-19 pandemic, with many investors backing firms that work to develop treatments for the virus.
Members of the Harvard Graduate Council elected Harvard Medical School student Peter Choi and Harvard School of Public Health student Himaja Nagireddy as the new president and vice president of the Council, respectively, during a virtual meeting Monday evening.
Since last year, the Council has conducted its elections virtually, with each of the 12 graduate schools allowed one vote. Choi, a first-year in the Medical School’s Master of Bioethics program, assumes the presidency after serving as Vice Chair of Governance. Nagireddy formerly served as Chair of Operations.
Chanthia C. Ma, the outgoing Council president, said she has “really high hopes” for Choi and Nagireddy’s ability to helm the organization in the months to come.
Siloed and Strained, Graduate Students Report Emotional Wellbeing as Obstacle to Online Learning | News thecrimson.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecrimson.com Daily Mail and Mail on Sunday newspapers.
The Globe and Mail Adam Mayers Published February 8, 2021
NanoStockk/iStockPhoto / Getty Images
Medical technology companies have been the stars of the health care sector for the past decade, but they met their match in 2020 when the COVID-19 pandemic arrived in full force.
Lockdowns during the past spring led to cancelled elective surgeries and slowed the pace of necessary surgeries. Patients were afraid to visit hospitals for check-ups and less urgent needs. And while many of the companies in this space are global, that didn’t help as the pandemic affected all of their markets.
That meant slim returns for investors. But with hopes that vaccinations will normalize conditions this year, is 2021 the year medtech bounces back?
(#28).
This year, guest bloggers played a particularly important role in advancing conversations about evangelicalism. Abram Van Engen warned about those Christians’ uses of American national mythology
(#9), then published a follow-up dialogue with one of the people he’d criticized: Os Guinness
(#19). Peter Choi, meanwhile, was not convinced that evangelicalism was actually addressing the problems brought to light by the Trump years
(#15 see that post’s comments section for Peter’s back-and-forth with one of the famous pastors he mentioned).
Other visiting writers went beyond evangelicalism to draw on other strands in church history, as when Joey Cochran clarified the historical meaning of the word “heresy”